{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Serious adverse events (SAEs) to be summarized by worst NCI NCI Common Terminology Criteria for Adverse Events (CTCAE) grade.","groups":[{"description":"Brentuximab vedotin will be given intravenously with a dose of 1.8 mg/kg every 21 days, over 30 minutes for 16 cycles in the clinic.","id":"OG000","title":"Brentuximab Vedotin Treatment"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants.","reportingStatus":"POSTED","timeFrame":"Up to 24 months post treatment","title":"Number of Participants With Study Related Serious Adverse Events (SAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}